Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biotech Walloped On Clinton Drug Price Controls Threat

This article was originally published in Scrip

Executive Summary

It was déjà vu all over again on Wall Street on Sept. 21 when biotech stocks took a beating after a powerful Washington politician vowed to take action to control prescription drug prices – a whipping reminiscent of March 2014 after three Democratic lawmakers set off a frenzy by suggesting they may pursue a similar path when they called on Gilead Sciences to explain its $1,000-per-pill price for its hepatitis C virus (HCV) medicine Sovaldi (sofosbuvir).

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts